Table 2. Cfl1 MO-induced epiboly defect can be partially rescued by co-injection of cfl1 mRNA, but not P53 MO.
| Treatments | Bud (%) | 90% epiboly (%) | 75% epiboly (%) | Death (%) | Number of embryos |
| StdMO | 97.0±4.2a | 0.8±1.7a | 0.0±0.0a | 2.2±4.4a | 149 |
| tMO1 | 9.7±6.8b | 28.6±14.2b | 53.3±26.4b | 8.4±9.6a | 166 |
| tMO1 + cfl1 mRNA | 49.6 ±11.8c | 36.9±7.7b | 8.7±10.7a | 4.8±4.0a | 160 |
| Un-injected | 96.6±4.0a | 0.7±1.3 a | 1.3±2.6 a | 1.4±2.8 a | 178 |
| tMO1 | 0.0±0.0 b | 7.9±10.7 b | 84.8±9.0 b | 7.3±4.8 b | 145 |
| tMO1 + p53 MO | 0.6±1.2 b | 7.9±7.5 b | 78.5±14.3 b | 13.0±10.6 b | 145 |
Note: Embryos at 1-cell stage were injected with cfl1 tMO1 (7.5 ng per embryo) without or with cfl1 mRNA (100 pg per embryo) or p53 MO (7.5 ng per embryo) and examined at 10 hpf. The percentages of epiboly progression were recorded. These experiments were repeated 4 times. Data are presented as means ± standard deviation. Experimental values are compared within groups, subjected to ANOVA and the mean separation was done by Duncan's Multiple Range Test (DMRT). Values with different lettering in their superscripts in the same column of each group are significantly (p<0.05) from each other.